小梁网途径的新型降眼压药物研究进展  

Research progress on novel intraocular pressure lowering drugs using trabecular meshwork pathway

作　　者：甘霈 刘雪珂 李霞 GAN Pei;LIU Xueke;LI Xia(Ophthalmology Specialty,Shihezi University School of Medicine,Shihezi 832099,Xinjiang Uygur Autonomous Region,China;Department of Ophthalmology,Xinjiang 474 Hospital,Urumqi 830013,Xinjiang Uygur Autonomous Region,China)

机构地区：[1]石河子大学医学院,新疆石河子832099 [2]新疆四七四医院眼科,新疆乌鲁木齐830013

出　　处：《世界临床药物》2024年第1期77-83,共7页World Clinical Drug

基　　金：新疆军区总医院北京路医疗区重点扶持科研项目(2022jzbjl18)。

摘　　要：青光眼(glaucoma)是一组以病理性眼压(intraocular pressure,IOP)升高为主要危险因素的神经退行性疾病,局部使用降IOP药物仍是其一线疗法。绝大部分房水经小梁网(trabecular meshwork,TM)途径外流,且TM途径是原发性开角型青光眼病变(primary open-angle glaucoma)的主要部位,故针对TM途径的新型降IOP药物对青光眼的治疗至关重要。现就近年来的Rho激酶抑制剂、一氧化氮供体及其他新型降IOP药物的作用机制及进展进行综述,旨在为临床提供参考。Glaucoma is a group of neurodegenerative diseases with pathological increase of intraocular pressure(IOP)as the main risk factor.Local use of IOP-lowering drugs is still the first line of treatment.Most of the aqueous humor flows out through the trabecular meshwork(TM)pathway,which is the main site of primary open-angle glaucoma.Therefore,novel IOP lowering drugs targeting the TM pathway are very important for the treatment of glaucoma.This article reviewed the mechanism and progress of Rho kinase inhibitors,nitric oxide donors and other novel IOP lowering drugs in recent years,aiming to provide clinical reference.

关 键 词：青光眼 小梁网 降眼压药物 药物治疗 

分 类 号：R775[医药卫生—眼科]